The Peripheral Neuropathy market was valued at USD 4.04 billion in 2023 and is expected to reach USD 7.95 billion by 2031 and grow at a CAGR of 8.9% over the forecast period of 2024-2031.
Peripheral neuropathy is said to be a physical condition where the nerves which acts as a communicator and which sends the signal to their central nervous system gets damaged, the major role of these nerves are to send sensory signals to the body parts but in peripheral condition the nerves gets damaged and because of which the body parts couldn’t receive the signal, the symptoms of peripheral neuropathy is divided into three groups Motor, Sensory and Autonomic, motor symptoms mainly include muscle weakness, cramps etc the Sensory symptoms include numbness, tickling etc autonomic symptoms include sweating, change in blood pressure, the rising cases of peripheral neuropathy all around the globe is the driving factor of the peripheral neuropathy market, doctors claim that the major reasons behind the cause of peripheral neuropathy is mainly because of excessive intake of alcohols, infections, and also people suffering from diabetes Product 2 are tend to get affected by peripheral neuropathy, according to our data there has been an increase of 70% in global alcohol intake which can also be contributing factor for the increase in the cases of peripheral neuropathy.
.png)
Get More Information on Peripheral Neuropathy Market - Request Free Sample Report
The impact of covid-19 affected several domains in healthcare because during COVID-19 the major objective of the healthcare sector in every nation was to prioritize the COVID patients and make sure they get proper treatment, patients suffering from other disease had to face a lot of problems which mostly included no access to hospitals no available slots, also the fear of coronavirus made it difficult for the other patients to visit the hospital on a regular basis, for many key players it was difficult to operate as the lockdown rules and regulations imposed by the government made it very difficult for them to function which impacted the demand and supply proportions and also it affected their supply chain management.
Drivers
Rise in the number of peripheral neuropathy cases all around the globe which positively impacts the demand.
Restrains
High cost of peripheral neuropathy treatment.
The cost of peripheral neuropathy is expensive which may hinder the market because people in emerging countries or underdeveloped regions it difficult for to manage their health expenses which will result in patients looking for inexpensive treatment.
The therapies that a patient needs to go through and which are considered as one form of treatment Product are expensive because the process and the latest technological which is used for giving therapies are expensive and which includes a huge cost factor that acts as a barrier for people with economic instability.
Opportunity
Technological advancement in the healthcare industry.
Campaigns and initiatives taken by the organizations and government to create awareness about peripheral neuropathy.
Challenge
Lack of skillful professionals and the lack of awareness in emerging countries.
Impact of Recession
According to our previous data, a recession brings a lot of change, especially in a decision-making perspective. According to the reports in the 2009 recession, people used to show up to the hospitals only in emergency cases and the regular visits decreased as the data says the cost of peripheral neuropathy is expensive so this might impact the market in a negative way, this report will give exact information about how the recession will impact the peripherical neuropathy market.
By Type
Diabetic Peripheral
Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
HIV/AIDS Associated Peripheral Neuropathy
By Treatment
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-Pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation,
Plasma Exchange
Intravenous Immune Globulin
Others
By End User
Hospitals and Clinics
Ambulatory Centers
Others
.png)
Need any customization research on Peripheral Neuropathy Market - Enquiry Now
The latest technology in the developed and emerging citers of North America is the reason this region will dominate the market, the rising cases of the peripheral neuropathy in this region and the rising awareness of the disease in North America are the factors that contribute to the growth of the peripheral neuropathy market in North America and also the latest development of the drugs and treatment facilities for the patients is said to be the factors because of which the growth is assured.
Europe will be the region with the second highest share because of the rising initiatives taken by the government in order to provide good facilities, build infrastructure and give a positive outlook for the healthcare sector which gives the peripheral neuropathy market the opportunity to show a good growth in this region during the forecasted period.
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Abbott Laboratories (US), Bristol Myers Squibb (US), Novartis AG (UK), Eli Lilly and Company (US), Pfizer Inc. (US), GlaxoSmithKline ple (UK), Merck and Co. Inc. (US), Cipla Limited (India), Lupin Limited (India), Reddy's Laboratories (India) & Other players.
WinSanTor – A development of a new drug to help people suffering from diabetic neuropathy.
Walk2Welness – The trail of Walkasins Lower Limb Sensory Prosthesis shows that these devices improve balance and sustainability decreases incidence of falls during long term use.
Elli Lilly ; Antidepressant Cymbalta which is used for the treatment of pain cause by the Diabetic Peripheral neuropathy gets approval for FDA and it is the first and only treatment which has got the approval
| Report Attributes | Details |
| Market Size in 2023 | US$ 4.04 Bn |
| Market Size by 2031 | US$ 7.95 Bn |
| CAGR | CAGR of 8.9% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Diabetic Peripheral, Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy) • By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies, Others) • By End User (Hospitals & Clinics, Ambulatory Care, Other) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles |
Abbott Laboratories (US), Bristol Myers Squibb (US), Novartis AG (UK), Eli Lilly and Company (US), Pfizer Inc. (US), GlaxoSmithKline ple (UK), Merck and Co. Inc. (US), Cipla Limited (India), Lupin Limited (India), Reddy's Laboratories (India) |
| Key Drivers | • Rise in the number of peripheral neuropathy cases all around the globe which positively impacts the demand. |
| Market Opportunities | • Technological advancement in the healthcare industry. • Campaigns and initiatives taken by the organizations and government to create awareness about the peripheral neuropathy. |
Ans: The Peripheral Neuropathy Market is growing at a CAGR of 3.5% Over the Forecast Period 2023-2030.
Rise in the number of peripheral neuropathy cases all around the globe which positively impacts the demand.
The latest technology in the developed and the emerging citers of the North America is the reason this region will dominate the market
High cost of peripheral neuropathy treatment.
Ans: The Peripheral Neuropathy Market Size is projected to reach US$ 7.44 Bn by 2030.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of the Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Peripheral Neuropathy Market Segmentation, By Type
8.1 Diabetic Peripheral
8.2 Neuropathy
8.3 Chemotherapy-induced Peripheral Neuropathy
8.4 Idiopathic Peripheral Neuropathy
8.5 HIV/AIDS Associated Peripheral Neuropathy
9. Peripheral Neuropathy Market Segmentation, By Treatment
9.1 Pharmacological Therapies
9.1.1 Pain Relievers
9.1.2 Anti-seizure Medications
9.1.3 Antidepressants
9.2 Non-Pharmacological Therapies
9.2.1 Transcutaneous Electrical Nerve Stimulation
9.2.2 Plasma Exchange
9.2.3 Intravenous Immune Globulin
9.3 Others
10. Peripheral Neuropathy Market Segmentation, by End User
10.1 Hospitals & Clinics
10.2 Ambulatory Centers
10.3 Others
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Global Peripheral Neuropathy Market by country
11.2.2North America Global Peripheral Neuropathy Market by Type
11.2.3 North America Global Peripheral Neuropathy Market by Treatment
11.2.4 North America Global Peripheral Neuropathy Market by End User
11.2.5 USA
11.2.5.1 USA Global Peripheral Neuropathy Market by Type
11.2.5.3 USA Global Peripheral Neuropathy Market by Treatment
11.2.5.4 USA Global Peripheral Neuropathy Market by End User
11.2.6 Canada
11.2.6.1 Canada Global Peripheral Neuropathy Market by Type
11.2.6.3 Canada Global Peripheral Neuropathy Market by Treatment
11.2.6.4 Canada Global Peripheral Neuropathy Market by End User
11.2.7 Mexico
11.2.7.1 Mexico Global Peripheral Neuropathy Market by Type
11.2.7.3 Mexico Global Peripheral Neuropathy Market by Treatment
11.2.7.4 Mexico Global Peripheral Neuropathy Market by End User
11.3 Europe
11.3.1 Europe Global Peripheral Neuropathy Market by country
1.3.3.2 Europe Global Peripheral Neuropathy Market by Type
11.3.3 Europe Global Peripheral Neuropathy Market by Treatment
11.3.4 Europe Global Peripheral Neuropathy Market by End User
11.3.5 Germany
11.3.5.1 Germany Global Peripheral Neuropathy Market by Type
11.3.5.2 Germany Global Peripheral Neuropathy Market by Treatment
11.3.5.3 Germany Global Peripheral Neuropathy Market by End User
11.3.6 UK
11.3.6.1 UK Global Peripheral Neuropathy Market by Type
11.3.6.2 UK Global Peripheral Neuropathy Market by Treatment
11.3.6.3 UK Global Peripheral Neuropathy Market by End User
11.3.7 France
11.3.7.1 France Global Peripheral Neuropathy Market by Type
11.3.7.2 France Global Peripheral Neuropathy Market by Treatment
11.3.7.3 France Global Peripheral Neuropathy Market by End User
11.3.8 Italy
11.3.8.1 Italy Global Peripheral Neuropathy Market by Type
11.3.8.2 Italy Global Peripheral Neuropathy Market by Treatment
11.3.8.3 Italy Global Peripheral Neuropathy Market by End User
11.3.9 Spain
11.3.9.1 Spain Global Peripheral Neuropathy Market by Type
11.3.9.2 Spain Global Peripheral Neuropathy Market by Treatment
11.3.9.3 Spain Global Peripheral Neuropathy Market by End User
11.3.10 The Netherlands
11.3.10.1 Netherlands Global Peripheral Neuropathy Market by Type
11.3.10.2 Netherlands Global Peripheral Neuropathy Market by Treatment
11.3.10.3 Netherlands Global Peripheral Neuropathy Market by End User
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Global Peripheral Neuropathy Market by Type
11.3.11.2 Rest of Europe Global Peripheral Neuropathy Market by Treatment
11.3.11.3 Rest of Europe Global Peripheral Neuropathy Market by End User
11.4 Asia-Pacific
11.4.1 Asia Pacific Global Peripheral Neuropathy Market by country
11.4.2 Asia Pacific Global Peripheral Neuropathy Market by Type
11.4.3 Asia Pacific Global Peripheral Neuropathy Market by Treatment
11.4.4 Asia Pacific Global Peripheral Neuropathy Market by End User
11.4.5 Japan
11.4.5.1 Japan Global Peripheral Neuropathy Market by Type
11.4.5.2 Japan Global Peripheral Neuropathy Market by Treatment
11.4.5.3 Japan Global Peripheral Neuropathy Market by End User
11.4.6 South Korea
11.4.6.1 South Korea Global Peripheral Neuropathy Market by Type
11.4.6.2 South Korea Global Peripheral Neuropathy Market by Treatment
11.4.6.3 South Korea Global Peripheral Neuropathy Market by End User
11.4.7 China
11.4.7.1 China Global Peripheral Neuropathy Market by Type
11.4.7.2 China Global Peripheral Neuropathy Market by Treatment
11.4.7.3 China Global Peripheral Neuropathy Market by End User
11.4.8 India
11.4.8.1 India Global Peripheral Neuropathy Market by Type
11.4.8.2 India Global Peripheral Neuropathy Market by Treatment
11.4.8.3 India Global Peripheral Neuropathy Market by End User
11.4.9 Australia
11.4.9.1 Australia Global Peripheral Neuropathy Market by Type
11.4.9.2 Australia Global Peripheral Neuropathy Market by Treatment
11.4.9.3 Australia Global Peripheral Neuropathy Market by End User
11.4.10 Rest of Asia-Pacific
11.4.10.1 APAC Global Peripheral Neuropathy Market by Type
11.4.10.2 APAC Global Peripheral Neuropathy Market by Treatment
11.4.10.3 APAC Global Peripheral Neuropathy Market by End User
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Global Peripheral Neuropathy Market by country
11.5.2 The Middle East & Africa Global Peripheral Neuropathy Market by Type
11.5.3 The Middle East & Africa Global Peripheral Neuropathy Market by Treatment
11.5.4 The Middle East & Africa Global Peripheral Neuropathy Market by End User
11.5.6 Israel
11.5.6.1 Israel Global Peripheral Neuropathy Market by Type
11.5.6.2 Israel Global Peripheral Neuropathy Market by Treatment
11.5.6.3 Israel Global Peripheral Neuropathy Market by End User
11.5.6 UAE
11.5.6.1 UAE Global Peripheral Neuropathy Market by Type
11.5.6.2 UAE Global Peripheral Neuropathy Market by Treatment
11.5.6.3 UAE Global Peripheral Neuropathy Market by End User
11.5.7 South Africa
11.5.7.1 South Africa Global Peripheral Neuropathy Market by Type
11.5.7.2 South Africa Global Peripheral Neuropathy Market by Treatment
11.5.7.3 South Africa Global Peripheral Neuropathy Market by End User
11.5.8 Rest of Middle East & Africa
11.5.8.1 Rest of Middle East & Asia Global Peripheral Neuropathy Market by Type
11.5.8.2 Rest of Middle East & Asia Global Peripheral Neuropathy Market Phase
11.5.8.3 Rest of Middle East & Asia Global Peripheral Neuropathy Market by End User
11.6 Latin America
11.6.1 Latin America Global Peripheral Neuropathy Market by country
11.6.2 Latin America Global Peripheral Neuropathy Market by Type
11.6.3 Latin America Global Peripheral Neuropathy Market by Treatment
11.6.4 Latin America Global Peripheral Neuropathy Market by End User
11.6.5 Brazil
11.6.5.1 Brazil Global Peripheral Neuropathy Market by Type
11.6.5.2Brazil Global Peripheral Neuropathy Market by Treatment
11.6.2.3 Brazil Global Peripheral Neuropathy Market by End User
11.6.6 Argentina
11.6.6.1 Argentina Global Peripheral Neuropathy Market by Type
11.6.6.3 Argentina Global Peripheral Neuropathy Market by Treatment
11.6.6.4 Argentina Global Peripheral Neuropathy Market by End User
11.6.7 Rest of Latin America
11.6.7.1 Rest of Latin America Global Peripheral Neuropathy Market by Type
11.6.7.3 Rest of Latin America Global Peripheral Neuropathy Market by Treatment
11.6.7.4 Rest of Latin America Global Peripheral Neuropathy Market by End User
12. Company Profile
12.1 Abbott Laboratories (US)
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Product /Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Bristol Myers Squibb (US)
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Product /Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Novartis AG (UK)
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Product /Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Eli Lilly and Company (US)
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Product /Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Pfizer Inc. (US)
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Product /Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 GlaxoSmithKline ple (UK)
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Product /Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Merck and Co. Inc. (US)
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Product /Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Cipla Limited (India)
12.8.1 Market Overview
12.8.2 Financials
12.8.3 Product /Services/Offerings
12.8.4 SWOT Analysis
12.6.5 The SNS View
12.9 Lupin Limited (India)
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Product /Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Reddy's Laboratories (India)
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Product /Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
14. Best Cases and Used Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Clinical Documentation Improvement Market Size was assessed to be worth USD 4.22 billion in 2022 and is expected to increment to USD 7.88 billion by 2030, extending at a CAGR of 8.1% from 2023 to 2030.
The Spinal Muscular Atrophy Treatment Market size was estimated USD 4.2billion in 2022 and is expected to reach USD 7.1 billion by 2030 at a CAGR of 6.9% during the forecast period of 2023-2030.
The Opioid Use Disorder Market size was valued at USD 3.13 billion in 2022 and it is expected to be worth around USD 6.15 billion by 2030 growing at a remarkable GAGR of 8.8% over the forecast period 2023-2030.
The Non-Invasive Fat Reduction Market Size was valued at USD 1.57 billion in 2022 and is expected to reach USD 5.33 billion by 2030, and grow at a CAGR of 16.5% over the forecast period 2023-2030.
The Blood Grouping Reagents Market Size was valued at USD 1.90 billion in 2022, and is expected to reach USD 4.11 billion by 2030 and grow at a CAGR of 10.1% over the forecast period 2023-2030.
The Foot Orthotic Insoles Market size was valued at USD 3.42 Billion in 2022 and is expected to reach USD 5.87 Billion By 2030 and grow at a CAGR of 7% over the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
